No retraction, correction or concern found when last checked on Oct 31, 2026.

EMT and inflammation: inseparable actors of cancer progression

Meggy Suarez‐Carmona, Julien Lesage, Didier Cataldo and 1 more

Molecular Oncology · 2017 · Review · CC BY

doi:10.1002/1878-0261.12095

Abstract

Tumors can be depicted as wounds that never heal, and are infiltrated by a large array of inflammatory and immune cells. Tumor‐associated chronic inflammation is a hallmark of cancer that fosters progression to a metastatic stage, as has been extensively reviewed lately. Indeed, inflammatory cells persisting in the tumor establish a cross‐talk with tumor cells that may result in a phenotype switch into tumor‐supporting cells. This has been particularly well described for macrophages and is referred to as tumor‐associated ‘M2’ polarization. Epithelial‐to‐mesenchymal transition (EMT), the embryonic program that loosens cell–cell adherence complexes and endows cells with enhanced migratory and invasive properties, can be co‐opted by cancer cells during metastatic progression. Cancer cells that have undergone EMT are more aggressive, displaying increased invasiveness, stem‐like features, and resistance to apoptosis. EMT programs can also stimulate the production of proinflammatory factors by cancer cells. Conversely, inflammation is a potent inducer of EMT in tumors. Therefore, the two phenomena may sustain each other, in an alliance for metastasis. This is the focus of this review, where the interconnections between EMT programs and cellular and molecular actors of inflammation are described. We also recapitulate data linking the EMT/inflammation axis to metastasis.

References 119

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis · 2015
No notice
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
Role of TGFβ in regulation of the tumor microenvironment and drug delivery (Review) · 2015
No notice
36.
Mesenchymal Transition and Dissemination of Cancer Cells Is Driven by Myeloid-Derived Suppressor Cells Infiltrating the Primary Tumor · 2011
No notice
37.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
The Inflammatory Chemokine CCL5 and Cancer Progression · 2014
No notice
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

All 119 references

Cited by papers we hold 22

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets · 2025
No notice
Targeting of TAMs: can we be more clever than cancer cells? · 2024
No notice
Pre-metastatic niche: formation, characteristics and therapeutic implication · 2024
No notice
Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy · 2024
No notice
Epithelial–mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities · 2022
No notice
Inflammation, Extracellular Matrix Remodeling, and Proteostasis in Tumor Microenvironment · 2021
No notice
miR-636 inhibits EMT, cell proliferation and cell cycle of ovarian cancer by directly targeting transcription factor Gli2 involved in Hedgehog pathway · 2021
Not checked
Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting · 2021
No notice
Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis · 2021
No notice
The Role of Tumor Inflammatory Microenvironment in Lung Cancer · 2021
No notice
Cancer drug resistance induced by EMT: novel therapeutic strategies · 2021
No notice
The Role of Macrophages in Cancer Development and Therapy · 2021
No notice
Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy · 2021
No notice
CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling · 2020
Not checked
Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance · 2020
No notice
Mechanisms of the Epithelial–Mesenchymal Transition and Tumor Microenvironment in Helicobacter pylori-Induced Gastric Cancer · 2020
No notice
C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights · 2020
No notice
Neutrophil Extracellular Traps (NETs) Promote Pro-Metastatic Phenotype in Human Breast Cancer Cells through Epithelial–Mesenchymal Transition · 2020
No notice
Fibronectin in Cancer: Friend or Foe · 2019
No notice
Contribution of Angiogenesis to Inflammation and Cancer · 2019
No notice

and 2 more

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.